TMBIM6 antagonist-1 (1 mg/kg, IP 5 days per week during 25 days) significantly impaires cell-driven tumor growth[1]. Animal Model: Six- to eight-week BklNbt:BALB/c/nu/nu old mice (HT1080 and MDA-MB-231 cells)[1]. Dosage: 1 mg/kg. Administration: IP 5 days per week during 25 days. Result: Impaired cell-driven tumor growth.
In Vitro
TMBIM6 antagonist-1 (BIA, 0.5-10 μM, 3 days) significantly and dose-dependently inhibits cell viability in HT1080, MCF7, MDA-MB-2341 and SKBR3 cells, with IC50 values of 1.7 ± 0.1 μM for HT1080, 2.6 ± 0.4 μM for MCF cells, 2.6 ± 0.5 μM for MDA-MB-231 cells, and 2.4 ± 0.4 μM for SKBR3 cells, respectively[1]. TMBIM6 antagonist-1 (BIA, 10 μM) treatment decreases cell migration in HT1080, MCF7, MDA-MB-231, and SKBR3 cells, not TMBIM6 KO HT1080 cells[1]. Cell Viability Assay[1] Cell Line: HT1080, MCF7, MDA-MB-2341 and SKBR3 cells. Concentration: 0.5-10 μM. Incubation Time: 3 days. Result: Inhibited cell viability. Western Blot Analysis[1] Cell Line: WT and TMBIM6 KO HT1080 cells. Concentration: 0, 2, 5 μM. Incubation Time: Result: Downregulated the protein levels of AKT-pS473.
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Hyun-Kyoung Kim, et al. TMBIM6/BI-1 contributes to cancer progression through assembly with mTORC2 and AKT activation. Nat Commun. 2020 Aug 11;11(1):4012.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
